Details of the Drug Combination

General Information of Drug Combination (ID: DCF7EI4)

Drug Combination Name
BVD-523 Marizomib
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs BVD-523   DMNB4XK Marizomib   DME9QGW
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: DIPG25
Zero Interaction Potency (ZIP) Score: 3.1
Bliss Independence Score: 5.85
Loewe Additivity Score: 3.35
LHighest Single Agent (HSA) Score: 5.37

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BVD-523
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Pancreatic cancer 2C10 Phase 1 [4]
BVD-523 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Extracellular signal-regulated kinase 1 (ERK1) TT1MG9E MK03_HUMAN Modulator [8]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Modulator [8]
Ephrin type-B receptor 2 (EPHB2) TTKPV6O EPHB2_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Marizomib
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Phase 3 [5]
Malignant glioma 2A00.0 Phase 1 [6]
Multiple myeloma 2A83 Phase 1 [6]
Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Marizomib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proteasome (PS) TTU7ZMG NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT03417739) A Phase II Study of BVD-523 in Metastatic Uveal Melanoma. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01781429) Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT03345095) A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma (MIRAGE). U.S. National Institutes of Health.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of Triphase Accelerator .
8 DOI: 10.1158/1538-7445.AM2015-4693
9 Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.